Measuring how long a cancer treatment extends life (overall survival, or OS) is the best way to judge its effectiveness. However, this data isn’t always available when doctors need to make treatment choices. Instead, they often rely on other measures like how long a patient lives without their cancer worsening (progression-free survival) or how well the treatment shrinks tumors (objective response rate). But these don’t always show the full long-term effects of treatment. A new initiative aims to create realistic models of real-world cancer treatment scenarios, including delayed benefits and crossover effects (where patients switch treatments). MMS, a company specializing in medical modeling, will lead this effort using its KerusCloud platform, which simulates cancer treatment outcomes and helps set decision-making guidelines. Jeff Allen, president of Friends of Cancer Research, said, ‘Quick access to new cancer treatments is crucial for patients, and this project is a big step toward making decisions faster and smarter.’ The collaboration between researchers, drug developers, and regulators will help them better understand early survival data, leading to faster and more informed decisions in cancer treatment development.